Correction to: Blood Cancer Journal 9:5
https://doi.org/10.1038/s41408-018-0169-1 published online 15 January 2019
After publication of the original article, the authors realised there was an incorrect image in Fig. S5B. The correct image is reproduced here. The Supplementary File of the original article has also been replaced with this error corrected. This error does not affect the conclusions drawn in the article.
⬛
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Moharram, S.A., Shah, K., Khanum, F. et al. Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia. Blood Cancer J. 9, 54 (2019). https://doi.org/10.1038/s41408-019-0214-8
Published:
DOI: https://doi.org/10.1038/s41408-019-0214-8
